Regulatory Development, Adoption, and Perseverance of Real-world Evidence with global health authorities

Real-world evidence (RWE) has gained significant attention as a valuable source of evidence in healthcare decision-making. This article provides a comprehensive analysis of the regulatory development, adoption, and perseverance of RWE with global health authorities, as well as a synopsis of the major trends and practices among global health authorities. The aim is to shed light on the current landscape, and prospects of utilizing RWE in regulatory processes. Globally, many health authorities are drafting guidelines for RWE and implementing various regulations. Implementation is in the initial stages because RWE has certain limitations. This article examines the experiences of selected global health authorities in the development and implementation of RWE strategies. It also examines regulatory guidelines, pilot programmes, and collaborations designed to establish a solid foundation for the use of RWE. However, despite all challenges and limitations, RWE is widely being used in drug approval and commercial sense.

Authors

Institutions

Publication Details

Journal
International Journal of Drug Regulatory Affairs
Published
2024-09-15
DOI
https://doi.org/10.22270/ijdra.v12i3.692
Primary Topic
Ethics in Clinical Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Regulatory Development, Adoption, and Perseverance of Real-world Evidence with global health authorities

Sanyam Gandhi, Akhilesh Tiwari, Vikas Jain, Sachin Jain et al.
International Journal of Drug Regulatory Affairs
Ethics in Clinical Research
article

Regulatory Development, Adoption, and Perseverance of Real-world Evidence with global health authorities

Sanyam Gandhi, Akhilesh Tiwari, Vikas Jain, Sachin Jain, C Kartikeyan, Kinshuk Saxena, Pradeep Pal
article en

Abstract

Real-world evidence (RWE) has gained significant attention as a valuable source of evidence in healthcare decision-making. This article provides a comprehensive analysis of the regulatory development, adoption, and perseverance of RWE with global health authorities, as well as a synopsis of the major trends and practices among global health authorities. The aim is to shed light on the current landscape, and prospects of utilizing RWE in regulatory processes. Globally, many health authorities are drafting guidelines for RWE and implementing various regulations. Implementation is in the initial stages because RWE has certain limitations. This article examines the experiences of selected global health authorities in the development and implementation of RWE strategies. It also examines regulatory guidelines, pilot programmes, and collaborations designed to establish a solid foundation for the use of RWE. However, despite all challenges and limitations, RWE is widely being used in drug approval and commercial sense.

International Journal of Drug Regulatory AffairsVol. 12(3)
Indira Gandhi National Tribal University (IN), Oriental University (RU), Novartis (United States) (US), Takeda (Japan) (JP), Vikram University (IN)
Openalex Percentile: Top 74%
Ethics in Clinical Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Regulatory Development, Adoption, and Perseverance of Real-world Evidence with global health authorities — Sanyam Gandhi, Akhilesh Tiwari, et al. · International Journal of Drug Regulatory Affairs (2024) | TGRS Research Map | TGRS